Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00338182 |
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 48-hour infusion every 14 days and as a 2-hour infusion for 2 consecutive days every 14 days in patients with advanced solid malignancies.
Condition | Intervention | Phase |
---|---|---|
Tumors |
Drug: AZD1152 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacokinetics Study |
Official Title: | A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 48-Hour Intravenous Infusion in Patients With Advanced Solid Malignancies |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |
Research Site | |
Boston, Massachusetts, United States | |
United States, New York | |
Research Site | |
New York, New York, United States |
Study Director: | Emerging Oncology Medical Science Director, MD | AstraZeneca |
Study ID Numbers: | D1531C00002 |
Study First Received: | June 16, 2006 |
Last Updated: | April 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00338182 |
Health Authority: | United States: Food and Drug Administration |
Solid tumor |